PUBLIC COMPANY
save$TYRATyra Biosciences, Inc.
$TYRA25.69-4.18%Carlsbad, CA, USupdated 1h ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
2Phase 11Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
- phase2Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
- phase2A Study of TYRA-300 in Children With Achondroplasia: BEACH301
- phase2Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- phase2Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
- phase1Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- phase1A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 25, 26SELLKAPLAN GILLA· director−$529K↗
routine RSU / option mechanics (6)
- Apr 16, 26grantDable Habib J · director44,400 sh
- Mar 26, 26dispo to issuerKAPLAN GILLA · director53,172 sh
- Mar 26, 26option exerciseKAPLAN GILLA · director53,172 sh
- Mar 26, 26option exerciseKAPLAN GILLA · director53,172 sh
- Mar 25, 26option exerciseKAPLAN GILLA · director14,295 sh
- Mar 25, 26option exerciseKAPLAN GILLA · director14,295 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that